Transgene Biotek Ltd.

BSE: TRABI526139ISIN INE773D01018

Healthcare
Healthcare Service Provider

Share price

₹2.57+0.17 (+7.08%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹4.19
52W low: ₹1.83
Off 52W high: -38.66%
1M return: +5.76%
3M return: -12.88%
6M return: -15.74%
1Y return: -28.21%
20D avg volume: 17,881
50 DMA: ₹2.62
200 DMA: ₹2.74

Key ratios Consolidated

Market cap: ₹16.90 Cr
Current price: ₹2.57
52W high / low: ₹4.19 / ₹1.83
Face value: ₹10.00
P/E: -12.11
P/B: —
EPS (TTM): ₹-0.21
Book value / share: —
ROE: —
ROCE: -0.50%
Operating margin: —
Net margin: —
Debt / equity: 2.05
Net debt: ₹17.08 Cr
Interest cover: -0.56
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -52.2 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	0.06	0.06	0.06	0.05	0.05	0.08	0.08	0.06	0.05	—
	0.00	0.15	0.00	0.00	0.00	0.04	0.04	0.04	0.65	—
	0.06	0.20	0.06	0.05	0.05	0.12	0.12	0.10	0.70	—
	0.45	0.66	0.43	0.44	0.48	0.83	0.21	0.18	0.50	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.03	0.03	0.03	0.03	0.05	0.06	0.08	0.08	0.08	—
	0.29	0.28	0.27	0.26	0.25	0.19	0.02	0.02	0.02	—
	0.04	0.05	0.05	0.05	0.05	0.02	0.02	0.02	0.02	—
	0.09	0.30	0.07	0.09	0.14	0.56	0.09	0.05	0.38	—
	-0.39	-0.46	-0.37	-0.39	-0.43	-0.71	-0.09	-0.07	0.20	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	-0.39	-0.46	-0.37	-0.39	-0.43	-0.71	-0.09	-0.07	0.20	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	-0.39	-0.46	-0.37	-0.39	-0.43	-0.71	-0.09	-0.07	0.20	—
	-0.05	-0.06	-0.05	-0.05	-0.06	-0.09	-0.01	-0.01	0.03	—
Key metrics
	-0.06	-0.13	-0.05	-0.08	-0.13	-0.50	-0.05	-0.03	0.24	—
	-100.00%	-216.70%	-83.30%	-160.00%	-260.00%	-625.00%	-62.50%	-50.00%	480.00%	—
	-650.00%	-766.70%	-616.70%	-780.00%	-860.00%	-887.50%	-112.50%	-116.70%	400.00%	—
	—	-0.10%	—	-0.10%	—	-0.40%	—	—	—	—
	20.00%	-25.00%	-25.00%	-16.70%	0.00%	—	—	—	—	—
	9.30%	35.20%	-311.10%	-457.10%	-315.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	0.23	0.21	0.26	—
	0.15	0.15	0.78	—
	0.37	0.36	1.04	—
	1.98	2.01	1.72	—
	0.00	0.00	0.00	—
	0.00	0.00	0.00	—
	0.12	0.15	0.31	—
	1.10	1.06	0.24	—
	0.19	0.20	0.09	—
	0.55	0.61	1.08	—
	-1.61	-1.65	-0.68	—
	0.00	0.00	0.00	—
	-1.61	-1.65	-0.68	—
	0.00	0.00	0.00	—
	-1.61	-1.65	-0.68	—
	-0.21	-0.22	-0.09	—
Key metrics
	-0.32	-0.39	-0.35	—
	-139.13%	-185.70%	-134.60%	—
	-700.00%	-785.70%	-261.50%	—
	—	-0.50%	-0.30%	—
	-14.81%	-19.20%	—	—
	—	-142.60%	—	—
	—	-0.01	1.20	—
	—	0.01	-1.76	—
	—	2.05	1.45	—
	—	17.08	14.24	—
	—	-52.2	-2,176.0	—
Balance sheet
	—	143.66	144.09	—
	—	1.03	1.26	—
	—	0.06	0.28	—
	—	0.01	0.01	—
	—	0.03	0.03	—
	—	0.92	0.00	—
	—	3.09	3.29	—
	—	0.07	1.59	—
	—	13.26	12.74	—
	—	17.14	14.52	—
	—	10.34	8.42	—
	—	6.80	6.10	—
	—	8.38	10.03	—
Cash flow
	—	-0.01	1.20	—
	—	0.15	-1.70	—
	—	-0.36	0.78	—
	—	0.00	0.00	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	0.06	0.06	0.06	0.05	0.05	0.08	0.08	0.06	0.05	—
	0.00	0.15	0.00	0.00	0.00	0.04	0.04	0.04	0.65	—
	0.06	0.20	0.06	0.05	0.05	0.12	0.12	0.10	0.70	—
	0.45	0.66	0.43	0.44	0.48	0.83	0.21	0.18	0.50	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.03	0.03	0.03	0.03	0.05	0.06	0.08	0.08	0.08	—
	0.29	0.28	0.27	0.26	0.25	0.19	0.02	0.02	0.02	—
	0.04	0.05	0.05	0.05	0.05	0.02	0.02	0.02	0.02	—
	0.08	0.30	0.07	0.09	0.14	0.56	0.09	0.05	0.38	—
	-0.39	-0.46	-0.37	-0.39	-0.43	-0.71	-0.09	-0.07	0.20	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	-0.39	-0.46	-0.37	-0.39	-0.43	-0.71	-0.09	-0.07	0.20	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	-0.39	-0.46	-0.37	-0.39	-0.43	-0.71	-0.09	-0.07	0.20	—
	-0.05	-0.06	-0.05	-0.05	-0.06	-0.09	-0.01	-0.01	0.03	—
Key metrics
	-0.06	-0.13	-0.05	-0.08	-0.13	-0.50	-0.05	-0.03	0.24	—
	-100.00%	-216.70%	-83.30%	-160.00%	-260.00%	-625.00%	-62.50%	-50.00%	480.00%	—
	-650.00%	-766.70%	-616.70%	-780.00%	-860.00%	-887.50%	-112.50%	-116.70%	400.00%	—
	—	-0.90%	—	-0.60%	—	-2.40%	—	—	—	—
	20.00%	-25.00%	-25.00%	-16.70%	0.00%	—	—	—	—	—
	9.30%	35.20%	-311.10%	-457.10%	-315.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	0.23	0.21	0.26	—
	0.15	0.15	0.78	—
	0.37	0.36	1.04	—
	1.98	2.01	1.72	—
	0.00	0.00	0.00	—
	0.00	0.00	0.00	—
	0.12	0.15	0.31	—
	1.10	1.06	0.24	—
	0.19	0.20	0.09	—
	0.54	0.61	1.08	—
	-1.61	-1.65	-0.68	—
	0.00	0.00	0.00	—
	-1.61	-1.65	-0.68	—
	0.00	0.00	0.00	—
	-1.61	-1.65	-0.68	—
	-0.21	-0.22	-0.09	—
Key metrics
	-0.32	-0.39	-0.35	—
	-139.13%	-185.70%	-134.60%	—
	-700.00%	-785.70%	-261.50%	—
	—	-2.90%	-2.00%	—
	-14.81%	-19.20%	—	—
	—	-142.60%	—	—
	—	-0.01	1.20	—
	—	0.01	-1.76	—
	—	-1.86	-1.92	—
	—	17.08	14.24	—
	—	-69.6	-2,190.0	—
Balance sheet
	—	33.76	34.18	—
	—	1.02	1.24	—
	—	0.06	0.28	—
	—	0.00	0.00	—
	—	0.03	0.03	—
	—	0.92	0.00	—
	—	3.09	3.29	—
	—	0.07	1.59	—
	—	13.14	12.62	—
	—	17.14	14.52	—
	—	10.34	8.42	—
	—	6.80	6.10	—
	—	-9.20	-7.57	—
Cash flow
	—	-0.01	1.20	—
	—	0.15	-1.70	—
	—	-0.36	0.78	—
	—	0.00	0.00	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -14.81%
Profit YoY (TTM): -23.85%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -14.81%
Profit YoY (TTM): -23.85%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 23.64%

Quarter	September 2026	June 2026	December 2016
Promoter %	23.64%	23.64%	23.64%

Holder	Type	Holding	Previous	Change
DR K KOTESWARA RAO	Promoter	21.89%	21.89%	0.00%
KOLLIPARA NIRMALA	Promoter	1.72%	1.72%	0.00%
KOLLIPARA SRINIVAS	Promoter	0.03%	0.03%	0.00%
Any Other(OTHER SHR OFF FAMILY)	Public	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Dr. Lal Pathlabs Limited	34,056	2,028.95	57.92	25.70%	+16.71% TTM	+8.93% TTM	+28.73%
Vijaya Diagnostic Centre Limited	14,676	1,424.85	72.05	19.20%	+24.48% TTM	+33.96% TTM	+39.02%
Metropolis Healthcare Limited	12,075	582.05	53.57	15.70%	+19.84% TTM	+41.90% TTM	+14.58%
Thyrocare Technologies Limited	7,883	495.25	55.01	33.60%	+21.99% TTM	+13.16% TTM	+9.41%
Nephrocare Health Services Limited	6,242	620.75	48.72	13.70%	—	—	—
SURAKSHA DIAGNOSTIC LIMITED	1,735	333.10	49.46	14.70%	+23.32% TTM	+7.94% TTM	+2.54%
Krsnaa Diagnostics Limited	1,566	482.90	15.97	10.60%	+15.90% TTM	+16.02% TTM	-37.25%
3B BlackBio Dx Limited	1,142	1,330.25	20.29	22.60%	+54.30% TTM	+14.75% TTM	-1.52%
HEALTH X PLATFORM LIMITED	863	271.20	-33.11	—	+28.85% TTM	+82.45% TTM	-8.73%
ONE GLOBAL SERVICE PROVIDER LIMITED S	861	440.70	11.65	65.70%	+161.55% TTM	+178.28% TTM	+21.17%
Gaudium IVF and Women Health Limited	779	107.05	—	23.10%	—	—	—
Aspira Pathlab & Diagnostics Limited S	144	140.35	-318.98	2.90%	+14.50% TTM	-117.58% TTM	+132.68%
Choksi Laboratories Ltd. S	142	203.90	65.77	12.30%	+10.74% TTM	+44.00% TTM	+38.05%
STAR IMAGING AND PATH LAB LIMITED	120	68.90	—	22.60%	—	—	-51.78%
MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED S	86	57.00	—	11.20%	—	—	—
Sharma East India Hospitals And Res S	34	87.05	24.11	14.20%	+14.13% TTM	-9.85% TTM	-38.28%
BANDARAM PHARMA PACKTECH LIMITED	34	19.03	25.81	4.70%	+114.59% TTM	+454.17% TTM	-22.14%
N.G.Industries Ltd. S	34	100.00	17.39	6.30%	+2.18% TTM	-74.06% TTM	-23.28%
Deccan Health Care Limited	29	12.00	11.40	3.20%	-0.37% TTM	+145.63% TTM	-29.41%
Chennai Meenakshi Multispeciality Hospital Ltd. S	27	36.78	-32.26	-2.80%	+0.08% TTM	+6.59% TTM	-29.27%
SAMSRITA LABS LIMITED	27	11.93	-3.33	-73.40%	—	—	-43.35%
Tejnaksh Healthcare Limited	26	12.83	21.19	5.90%	-12.97% TTM	-33.15% TTM	-27.02%
Transgene Biotek Ltd.	17	2.57	-12.11	-0.50%	-14.81% TTM	-23.85% TTM	-28.21%
Dolphin Medical Services Ltd. S	11	7.11	59.25	0.60%	-1.25% TTM	+700.00% TTM	+246.83%
Looks Health Services Limited S	11	10.08	504.00	0.20%	-41.89% TTM	-57.14% TTM	+101.20%

Filings & corporate actions

Recent announcements

1. RESIGNATION OF M/S. HARISH GUMMADI & CO., CHARTERED ACCOUNTANTS: The Board took note of the resignation letter dated 03rd November, 2026, submitted by M/s. Harish Gummadi & Co., Chartered ....4 Nov 2026 · Others / Outcome without intimation
Intimation of Resignation of Statutory of Auditors - M/S. Harish Gummadi & Co.., Chartered Accountants.4 Nov 2026 · Company Update / Resignation of Statutory Auditors
1. APPOINTMENT OF STATUTORY AUDITORS TO FILL THE CASUAL VACANCY: The Board of Directors, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Harish ....2 Nov 2026 · Others / Outcome without intimation
Submission of Additional Details Pursuant to BSE Observation -Resignation of Statutory Auditors under Regulation 30 of SEBI (LODR) Regulations, 2015.31 Oct 2026 · Company Update / Resignation of Statutory Auditors
Submission of Additional Details pursuant to BSE Observation -Resignation of Statutory Auditors under Regulation 30 of SEBI (LODR) Regulation, 2015.31 Oct 2026 · Company Update / Resignation of Statutory Auditors
Submission of Additional Details pursuant to BSE Observation -Resignation of Statutory Auditor under Regulation 30 of SEBI (LODR) Regulations, 2015.31 Oct 2026 · Company Update / Resignation of Statutory Auditors
Intimation of Resignation of Statutory Auditors -M/s. Eswara Rao & Co., Chartered Accountants.29 Oct 2026 · Company Update / Resignation of Statutory Auditors
Appointment of Statutory Auditors to fill the Casual Vacancy The Board of Directors, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Eswara Rao ....10 Oct 2026 · Board Meeting / Outcome of Board Meeting
Statement of Deviation & Variation, 30-09-2026.3 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Compliance -57(5) Intimation after the end of quarter3 Oct 2026 · Others / 57 (5) : intimation after the end of quarter
Compliance -57(4)3 Oct 2026 · Others / 57 (4) : Prior intimation to the beginning of the quarter
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....3 Oct 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Compliance Certificate 7(3) as on 30-09-2026.3 Oct 2026 · Company Update / Reg. 7(3) – Compliance Certificate (RTA & Compliance Officer)
Compliances Certificate under Reg. 74(5)3 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/10/2026 ,inter alia, to consider and approve To consider and approve the ....2 Oct 2026 · Board Meeting / Board Meeting
Intimation Extension of time for holding 36th Annual General Meeting of the Company for the Financial year ended on March 31, 2026.25 Sep 2026 · Company Update / General
Intimation of Resignation of Statutory Auditors-M/s. Vasavi & Co., Chartered Accountants (FRN:020965S).23 Sep 2026 · Company Update / Resignation of Statutory Auditors
Closure of Trading Window22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Closure of Trading Window22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication11 Aug 2026 · Company Update / Newspaper Publication
Unaudited Financial Results for the quarter ended 30th June 2026.7 Aug 2026 · Result / Financial Results
Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of ....7 Aug 2026 · Board Meeting / Outcome of Board Meeting
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....23 Jul 2026 · Board Meeting / Board Meeting
Compliance - 57(4)22 Jul 2026 · Others / 57 (4) : Prior intimation to the beginning of the quarter
Statement of Deviation & Variation22 Jul 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Compliance -57 (5)22 Jul 2026 · Others / 57 (5) : intimation after the end of quarter
Compliances - Certificate under Reg. 74(5) of SEBI13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window20 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.2 Jun 2026 · Company Update / Newspaper Publication
Audited Financial Results29 May 2026 · Result / Financial Results
This has reference to our letter dated May 13, 2026, The Board of Directors of the Company at their meeting held on May 29, 2026 have resolved as follows: Pursuant to Regulation 33 of ....29 May 2026 · Board Meeting / Outcome of Board Meeting
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve To Consider and approve the ....15 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....13 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Non-Applicability of Regulation 32(1) of SEBI.13 Apr 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Compliance - 57 (4)13 Apr 2026 · Others / 57 (4) : Prior intimation to the beginning of the quarter
Non-Applicability of Reg -57 (5) of SEBI LODR Regulations, 2015.13 Apr 2026 · Others / 57 (5) : intimation after the end of quarter
Compliance certificate 7(3)13 Apr 2026 · Company Update / Reg. 7(3) – Compliance Certificate (RTA & Compliance Officer)
Compliances Certificate under 74 (5) of SEBI13 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window24 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication17 Feb 2026 · Company Update / Newspaper Publication

Board meetings

7 Aug 2026 Board Meeting - Financial Results